Cancer Prevention Agent Development: Waiting for Godot? - Howard Bailey, MD
Upon completion of this activity, participants will be able to:
- Identify FDA approved cancer prevention agents.
- Describe current pathways for testing cancer prevention agents.
- Critically review clinical trials in cancer prevention.
|Howard H. Bailey, MD |
|Elizabeth R. Trowbridge, MD|
|Samantha Murray-Bainer, MD|
|Gretchen Olson, BS|
|Kristen Panther, NP|
It is the policy of the University of Wisconsin–Madison ICEP that the faculty, authors, planners, and other persons who may influence content of this CE activity disclose all relevant financial relationships with commercial interests* in order to allow CE staff to identify and resolve any potential conflicts of interest. Faculty must also disclose any planned discussions of unlabeled/unapproved uses of drugs or devices during the educational activity. For this educational activity all conflicts of interests have been resolved and detailed disclosures are listed below:
Howard H. Bailey, MD: No relevant relationships to disclose in regard to this activity.
Elizabeth R. Trowbridge, MD: No relevant relationships to disclose in regard to this activity.
Gretchen Olson, BS: No relevant relationships to disclose in regard to this activity.
Kristen Panther, NP: No relevant relationships to disclose in regard to this activity.
Jennifer Pulley: No relevant relationships to disclose in regard to this activity.
Samantha Murray-Bainer, MD: No relevant relationships to disclose in regard to this activity.
Jessica Carlucci-Jenkins, BA: No relevant relationships to disclose in regard to this activity.
Kim Spreacker, PhD: No relevant relationships to disclose in regard to this activity.
* The ACCME defines a commercial interest as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.
Disclosure of Unlabeled Use: The University of Wisconsin–Madison ICEP advises the participant that this continuing medical education activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices.
|In support of improving patient care, the University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.|
Credit Designation Statements
American Board of Internal Medicine
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Medical Association
The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC)
The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 ANCC contact hour.
The University of Wisconsin–Madison School of Nursing is Iowa Board of Nursing provider 350.
Continuing Education Units
The University of Wisconsin–Madison, as a member of the University Continuing Education Association (UCEA), authorizes this program for .01 continuing education units (CEUs) or 1 hour.
- 1.00 MOC: ABIM Medical Knowledge Points (Part II)
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC Contact Hours
- 1.00 University of Wisconsin–Madison Continuing Education Hours